Dapagliflozin + Linagliptin FDC vs Linagliptin Alone in Indian T2DM Patients: What the 2024 Trial Found
A multi-centre, randomised clinical trial conducted at 16 sites across India has found that a fixed-dose combination (FDC) of Dapagliflozin 10mg + Linagliptin 5mg produced significantly greater HbA1c reduction than Linagliptin 5mg alone in patients with type 2 diabetes mellitus (T2DM) already treated with Metformin.
The study was published in Diabetes Therapy (Springer), Volume 15, pages 215-227, 2024, online 14 November 2023. DOI: 10.1007/s13300-023-01504-3.
Study Design at a Glance
| Parameter | Detail |
|---|---|
| Study design | Randomised, double-blind, parallel-group |
| Sites | 16 centres across India |
| Enrolment period | August 2022 - April 2023 |
| Patients screened | 287 |
| Patients randomised (1:1) | 232 |
| Patients completing study | 225 (115 FDC group, 110 Linagliptin group) |
| Background therapy | Metformin monotherapy (all patients) |
| Test intervention | Dapagliflozin 10mg + Linagliptin 5mg FDC once daily |
| Reference intervention | Linagliptin 5mg once daily |
| Primary endpoint | Change in HbA1c from baseline at 16 weeks |
| Journal | Diabetes Therapy (Springer), Vol 15, pp 215-227, 2024 |
Primary Result: HbA1c Reduction
| Group | Mean HbA1c reduction at 16 weeks | p-value vs comparator |
|---|---|---|
| FDC: Dapagliflozin 10mg + Linagliptin 5mg | −1.28% | 0.0003 |
| Linagliptin 5mg alone | −0.83% |
The absolute difference was 0.45 percentage points in favour of the FDC, and this was statistically significant (p = 0.0003). Both groups continued their background Metformin throughout the study.
Why Two Different Mechanisms Work Together
The two drugs in this FDC work through entirely different pathways - which is why the combination produces additive benefit rather than redundancy:
Dapagliflozin (SGLT2 Inhibitor)
Dapagliflozin blocks sodium-glucose co-transporter 2 (SGLT2) in the renal proximal tubule, preventing glucose reabsorption and causing glucose excretion via urine (glucosuria). This mechanism is entirely insulin-independent - it works regardless of how much insulin the patient produces or how insulin-resistant they are. Beyond glycaemic control, Dapagliflozin has demonstrated:
- Cardiovascular benefit in T2DM patients with established cardiovascular disease (DECLARE-TIMI 58 trial)
- Heart failure hospitalisation reduction (DAPA-HF trial - even in patients without T2DM)
- Renal protection in chronic kidney disease (DAPA-CKD trial)
- Modest reductions in blood pressure and body weight
Linagliptin (DPP-4 Inhibitor)
Linagliptin inhibits dipeptidyl peptidase-4 (DPP-4), the enzyme that inactivates the incretin hormones GLP-1 and GIP. By blocking DPP-4, Linagliptin extends the activity of GLP-1 and GIP, which stimulate glucose-dependent insulin secretion and suppress glucagon. Key properties:
- Glucose-dependent action - does not cause hypoglycaemia when used without insulin or sulfonylureas
- Renally neutral - Linagliptin is unique among DPP-4 inhibitors in not requiring dose adjustment in renal impairment, making it one of the preferred choices for T2DM patients with CKD
- No significant effect on weight or blood pressure
The combination of an insulin-independent renal glucose-excretion mechanism (Dapagliflozin) with an insulin-stimulating mechanism (Linagliptin) covers complementary pathophysiological targets in T2DM - justifying the FDC rationale.
Connection to CDSCO Approvals
This study provides part of the Indian clinical evidence base for SGLT2 inhibitor + DPP-4 inhibitor FDCs. CDSCO approved the Dapagliflozin 5mg + Linagliptin 5mg FDC on 11 January 2024, and the triple Empagliflozin + Linagliptin + Metformin ER FDC on 14 January 2025.
Indian multi-centre clinical trials like this one - conducted in real Indian patient populations across multiple sites - are part of the data package considered for Indian FDC approvals under Rule 122E of the Drugs and Cosmetics Rules.
Limitations of This Study
- Duration: 16 weeks is shorter than standard T2DM trial durations. Long-term cardiovascular, renal, and safety outcomes were not assessed in this study. The established outcomes data for these individual drugs comes from larger, longer trials (DECLARE-TIMI 58 for Dapagliflozin; CARMELINA for Linagliptin).
- Comparator: The study compared the FDC against Linagliptin alone - not against Dapagliflozin alone, or against other add-on strategies (GLP-1 receptor agonists, sulfonylureas, basal insulin). The finding demonstrates superiority over a DPP-4 inhibitor alone, not over all possible treatment intensification strategies.
- Background therapy: All patients were on Metformin monotherapy at baseline. The findings apply specifically to Metformin-treated patients requiring further glycaemic control - they may not generalise to patients on other or multiple background therapies.
- Open-label aspects: While described as double-blind, the double-dummy design details should be reviewed in the full paper for any potential for bias.
Full Citation
Dapagliflozin/Linagliptin Fixed-Dose Combination Versus Linagliptin in Type 2 Diabetes Mellitus: A Multicenter, Randomized, Double-Blind Clinical Trial.
Journal: Diabetes Therapy (Springer), Volume 15, pages 215-227 (2024).
Published online: 14 November 2023.
DOI: 10.1007/s13300-023-01504-3
Sources
- Dapagliflozin/Linagliptin Fixed-Dose Combination Versus Linagliptin in Type 2 Diabetes Mellitus: A Multicenter, Randomized, Double-Blind Clinical Trial. Diabetes Therapy, Vol 15, pp 215-227, 2024. DOI: 10.1007/s13300-023-01504-3 (Springer)
- CDSCO. Fixed Dose Combinations Approved by DCG(I) - January 2024 to March 2025. Central Drugs Standard Control Organisation. cdsco.gov.in
This article is a summary of a published peer-reviewed study for informational purposes. It does not constitute clinical advice. Prescribing decisions for T2DM should be guided by current clinical guidelines (ADA, RSSDI, ICMR), individual patient factors including renal function and cardiovascular risk, and individual physician judgment. Read the full paper for complete methodology and safety data.
